 |
| |
| Apr-23-18 | Upgrade |
Goldman |
Neutral → Buy |
|
|
| Apr-17-18 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
| Apr-05-18 | Upgrade |
Barclays |
Equal Weight → Overweight |
$62 → $64 |
|
| Mar-12-18 | Upgrade |
Leerink Partners |
Mkt Perform → Outperform |
|
|
| Feb-14-18 | Reiterated |
Leerink Partners |
Mkt Perform |
$67 → $66 |
|
| Feb-07-18 | Reiterated |
Morgan Stanley |
Equal-Weight |
$60 → $63 |
|
| Jan-16-18 | Upgrade |
SunTrust |
Hold → Buy |
|
|
| Nov-28-17 | Resumed |
BofA/Merrill |
Buy |
$64 |
|
| Nov-24-17 | Reiterated |
Deutsche Bank |
Hold |
$62 → $59 |
|
| Oct-31-17 | Upgrade |
Jefferies |
Underperform → Hold |
|
|
| Oct-30-17 | Downgrade |
SunTrust |
Buy → Hold |
|
|
| Oct-30-17 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
|
|
| Oct-30-17 | Downgrade |
Barclays |
Overweight → Equal Weight |
$72 → $62 |
|
| Oct-18-17 | Upgrade |
Citigroup |
Neutral → Buy |
|
|
| Aug-09-17 | Upgrade |
HSBC Securities |
Reduce → Hold |
|
|
| Jul-31-17 | Reiterated |
UBS |
Buy |
$70 → $72 |
|
| Jan-13-17 | Initiated |
Bryan Garnier |
Buy |
|
|
| Jan-12-17 | Upgrade |
Piper Jaffray |
Neutral → Overweight |
|
|
| Jan-12-17 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
| Jan-12-17 | Upgrade |
Guggenheim |
Neutral → Buy |
|
|
|
|
| May-23-18 06:32PM | Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward TheStreet.com |
| 05:56PM | Why Big Pharma is finally discovering the Bay Area American City Business Journals |
| 04:43PM | Ebola patients slip out of Congo hospital as medics try to curb outbreak Reuters |
| 03:24PM | 7 S&P 500 Companies Doing Right for Employees InvestorPlace |
| 11:57AM | Merck's cancer drug Keytruda notches another trial success Reuters |
| 10:55AM | Why the world needs more than one Ebola vaccine Reuters |
| 07:46AM | Three Ebola patients escape Congo quarantine, medics race to control outbreak Reuters |
| 07:30AM | Mercks experimental and unlicensed Ebola vaccine is being used in latest outbreak MarketWatch |
| 06:45AM | Mercks KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (NSCLC) in Pivotal Phase 3 KEYNOTE-407 Trial Business Wire |
| 06:11AM | Three Ebola patients escape quarantine in Congo, two later die - MSF Reuters |
| May-22-18 02:21PM | Merck Announces Third-Quarter 2018 Dividend Business Wire |
| 12:25AM | [$$] Ebola Vaccination Begins in Democratic Republic of Congo The Wall Street Journal |
| May-21-18 04:53PM | [$$] Ebola Vaccination Begins in Democratic Republic of Congo The Wall Street Journal |
| 10:49AM | Factbox - From sterling crises to Brexit, the tests of Bank of England bosses Reuters |
| 10:35AM | Congo begins giving experimental Ebola vaccine to medics Reuters |
| 09:40AM | 7 Blue-Chip Stocks That Arent Blue Chips at All InvestorPlace |
| May-20-18 07:42AM | Congo to begin Ebola vaccinations on Monday - health ministry Reuters |
| May-18-18 11:13AM | 3 Dow Stocks to Buy With Dividends Yielding More Than 3% Motley Fool |
| 06:00AM | Why J&J's Stock May Plunge 10% Investopedia |
| May-17-18 11:27AM | Investors Need to Adopt a Different Mindset for Big Pharma and Biotech Stocks InvestorPlace |
| 10:03AM | Roche Tecentriq Combo Achieves Longer Overall Survival Rate Zacks |
| 09:16AM | The Zacks Analyst Blog Highlights: Home Depot, Merck, Raytheon, Eaton and Sun Life Financial Zacks |
| May-16-18 06:10PM | Roche immunotherapy combination increases lung cancer survival-study Reuters |
| 05:32PM | Merck's Keytruda boosts response in hard-to-treat lung cancer Reuters |
| 05:05PM | New Data from Mercks Leading Immuno-Oncology Clinical Development Program in Over 25 Tumor Types to Be Presented at 2018 ASCO Annual Meeting Business Wire |
| 02:37PM | MARKETS: Russell 2000 hits all-time high; Walmart earnings on deck; oil prices reverse; healthcare stocks in focus Yahoo Finance Video |
| 10:54AM | Top Analyst Reports for Home Depot, Merck & Raytheon Zacks |
| May-15-18 01:31PM | Ebola Vaccine Headed to Congo to Help Contain Outbreak The Wall Street Journal |
| 10:32AM | Merck KGaA (MKGAF) Q1 Earnings and Revenues Decline Y/Y Zacks |
| 08:00AM | Free Stock Performance Review on Pfizer and Three More Drug Makers Stocks ACCESSWIRE |
| 03:44AM | Merck KGaA Sees Profit Falling on Liquid Crystals Struggle Bloomberg Video |
| 03:44AM | Merck KGaA Sees Profit Falling on Liquid Crystals Struggle Bloomberg |
| 02:44AM | [$$] Merck KGaA's Sales Fall The Wall Street Journal |
| 01:47AM | Merck KGaA Q1 earnings down on liquid crystals, currencies Reuters |
| 01:21AM | Merck KGaA Q1 earnings down on liquid crystals, currencies Reuters |
| May-14-18 08:35PM | Merck & Co Inc. (NYSE:MRK) Is Trading At A 31% Discount Simply Wall St. |
| 01:25PM | The Trump Plan To Reduce Prescription Drug Prices Will Have A Major Impact Forbes |
| 09:40AM | What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings? Zacks |
| 08:32AM | Dow Posts Longest Stretch of Gains in 6 Months: 4 Picks Zacks |
| May-13-18 06:31AM | Better Buy: Pfizer Inc. (PFE) vs. Merck (MRK) Motley Fool |
| May-12-18 09:28AM | Is Agenus Inc. (AGEN) a Buy? Motley Fool |
| May-11-18 05:02PM | Trump lets drug companies off the hook Yahoo Finance Video |
| 10:17AM | US stock indexes edge higher in early trading; oil down Associated Press |
| 10:13AM | Trump to announce ways to lower prescription drug costs Yahoo Finance Video |
| 09:28AM | WHO hopes to use Ebola vaccine to stem outbreak in remote area of Congo Reuters |
| 09:25AM | Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings? Zacks |
| May-10-18 05:50PM | Big Peninsula biotech buyout means happy returns for Kleiner Perkins, other VCs American City Business Journals |
| May-09-18 04:27PM | Johnson & Johnson Stock Looks Attractive on the Big Dip InvestorPlace |
| 07:30AM | Wired News Merck to Expand Use of Veeva Systems CRM in Latin America and Asia/Pacific ACCESSWIRE |
| May-08-18 03:59PM | Agenus' (AGEN) Q1 Loss Wider than Expected, Shares Down Zacks |
| 06:45AM | LYNPARZA® (olaparib) Tablets Receive EU Approval for the Treatment of Platinum-Sensitive Relapsed Ovarian Cancer Business Wire |
| May-06-18 07:47AM | Merck & Co Inc. (NYSE:MRK): Time For A Financial Health Check Simply Wall St. |
| May-04-18 04:06PM | Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication Zacks |
| 12:13PM | Is Trump Willing To Do What It Takes To Reduce High Prescription Drug Prices? Forbes |
| 06:00AM | Eli Lilly Shares Seen Rising 18% as Profits Surge Investopedia |
| May-03-18 05:48PM | Biotech unicorn Moderna raises another $125M from partner Merck American City Business Journals |
| 04:15PM | Moderna and Merck Expand mRNA Cancer Vaccines Collaboration Business Wire |
| 06:45AM | Merck Provides Update on KEYNOTE-407 Trial Business Wire |
| 05:31AM | Merck KGaA family says unreservedly behind the pharma unit Reuters |
| 05:28AM | Merck KGaA CEO Happy With Portfolio, Celebrating 350th Year of Existence Bloomberg Video |
| 05:27AM | Merck KGaA CEO Happy With Portfolio, Celebrating 350th Year of Existence Bloomberg |
| May-02-18 10:17AM | Company News for May 2, 2018 Zacks |
| 09:36AM | Merck, Pfizer Deliver Checkup on Pharma Sector Bloomberg Video |
| 08:04AM | Markets Await Confirmation of a June Rate Hike InvestorPlace |
| 08:00AM | Why You Should Ditch Growth Stocks, Buy Value Investopedia |
| May-01-18 03:02PM | 3 Numbers That Should Grab Your Attention in Merck's Q1 Earnings Motley Fool |
| 02:52PM | Edited Transcript of MRK earnings conference call or presentation 1-May-18 12:00pm GMT Thomson Reuters StreetEvents |
| 01:34PM | MARKETS: Stocks are selling off on the ISM miss, which also reveals problems in the factory sector Yahoo Finance Video |
| 12:32PM | Merck dips, Under Armour slips, NutriSystem rips Yahoo Finance |
| 12:26PM | Merck Company Inc. (MRK) Q1 2018 Earnings Conference Call Transcript Motley Fool |
| 12:09PM | Merck posts strong first-quarter profit, but revenue light Associated Press |
| 11:58AM | Keytruda sales power Merck to quarterly beat Reuters |
| 11:11AM | Health-Care Earnings: Merck, Pfizer Disappoint With Q1 Revenue Barrons.com |
| 10:58AM | Mercks Dangerous Keytruda Success Bloomberg |
| 10:50AM | Merck (MRK) Beats on Q1 Earnings, Lags Sales, Raises Outlook Zacks |
| 10:23AM | Apple Results, Fed Decision, Jobs Report In Focus; Merck, Pfizer Reports Mixed Benzinga |
| 09:30AM | Don't Throw in the Towel on Merck After Earnings Selloff TheStreet.com |
| 08:52AM | Continue to Hold Longs in Merck, New Targets Seen TheStreet.com |
| 08:24AM | Benzinga Pro's 5 Stocks To Watch Today Benzinga |
| 07:16AM | Keytruda powers Merck to first-quarter beat Reuters |
| 07:14AM | Merck shares lift after Q1 profit beat, sales miss MarketWatch |
| 07:12AM | Merck (MRK) Tops on Q1 Earnings, Misses Sales Zacks |
| 06:45AM | Merck Announces First-Quarter 2018 Financial Results Business Wire |
| Apr-30-18 12:46PM | These big pharma names report earnings tomorrow CNBC Videos |
| 11:58AM | Pharmaceutical Earnings: Pfizer And Merck Are Slated To Report Tuesday Morning Benzinga |
| 10:11AM | Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More Zacks |
| 08:20AM | Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Merck & Co. ACCESSWIRE |
| 07:07AM | Merck has submitted Keytruda combination for FDA approval MarketWatch |
| 06:45AM | FDA Grants Priority Review to Mercks sBLA for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy Based on Results from Phase 3 KEYNOTE-189 Trial as First-Line Treatment of Metastatic Nonsquamous NSCLC Business Wire |
| Apr-29-18 08:39AM | Economic Calendar - Top 5 Things to Watch This Week Investing.com |
| Apr-27-18 04:52PM | What to Expect From Allergan, Aetna, Merck and Pfizer's Earnings Next Week TheStreet.com |
| 03:12PM | BMO Sees Balanced Risk-Reward In Bristol-Myers, Takes Neutral Position Benzinga |
| Apr-26-18 02:09PM | Bristol's Case for Opdivo Optimism Has Shaky Foundations Bloomberg |
| 09:20AM | Merck vs. Pfizer: Which Stock is Better Before Q1 Earnings? Zacks |
| Apr-25-18 05:31PM | U.S. court upholds dismissal of $200 mln Merck verdict against Gilead Reuters |
| 03:28PM | U.S. court upholds dismissal of $200 million Merck verdict against Gilead Reuters |
| 08:59AM | Merck Gets Another Upgrade Thanks To Keytruda Investing.com |
| 08:03AM | What's in the Cards for Merck (MRK) This Earnings Season? Zacks |
| Apr-24-18 08:32AM | Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma Motley Fool |
| 08:08AM | The Treasury Yield Is Trembling on the Edge of 3% InvestorPlace |
|
|
|
|
| Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., and IO Biotech. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Gerberding Julie L. | EVP Strat Comm, Gl Pub Policy | May 15 | Sale | 59.66 | 9,972 | 594,963 | 45,717 | May 16 12:33 PM | | Watson Ashley | SVP Chief Ethics & Com Officer | May 01 | Option Exercise | 0.00 | 10,441 | 0 | 12,783 | May 02 12:19 PM | | Chattopadhyay Sanat | Exe V-P & Pres. MMD | May 01 | Option Exercise | 0.00 | 4,009 | 0 | 52,609 | May 02 12:18 PM | | Karachun Rita A | Sr. VP Fince-Global Controller | May 01 | Option Exercise | 0.00 | 3,007 | 0 | 22,205 | May 02 12:18 PM | | GRADDICK WEIR MIRIAN M | Exe V-P, HR | Apr 16 | Sale | 58.00 | 24,000 | 1,392,000 | 80,433 | Apr 17 05:56 PM | | WEEKS WENDELL P | Director | Feb 09 | Option Exercise | 38.04 | 5,000 | 190,200 | 5,100 | Feb 09 04:48 PM | | DeLuca Richard R. | EVP&Pres, Merck Animal Health | Feb 09 | Option Exercise | 0.00 | 8,572 | 0 | 45,780 | Feb 09 04:48 PM | | WEEKS WENDELL P | Director | Feb 09 | Sale | 53.57 | 5,000 | 267,833 | 100 | Feb 09 04:48 PM | | Schechter Adam H | EVP & Pres-Global Human Health | Jan 16 | Option Exercise | 36.56 | 50,994 | 1,864,341 | 50,994 | Jan 16 05:13 PM | | GRADDICK WEIR MIRIAN M | Exe V-P, HR | Jan 16 | Option Exercise | 44.30 | 52,000 | 2,303,600 | 153,484 | Jan 16 05:12 PM | | Holston Michael J | EVP, General Counsel | Jan 16 | Sale | 61.63 | 12,500 | 770,375 | 49,092 | Jan 16 05:13 PM | | Schechter Adam H | EVP & Pres-Global Human Health | Jan 16 | Sale | 61.63 | 50,608 | 3,118,971 | 62,766 | Jan 16 05:13 PM | | Schechter Adam H | EVP & Pres-Global Human Health | Jan 16 | Sale | 61.63 | 50,994 | 3,142,760 | 0 | Jan 16 05:13 PM | | GRADDICK WEIR MIRIAN M | Exe V-P, HR | Jan 16 | Sale | 61.63 | 60,000 | 3,697,800 | 93,484 | Jan 16 05:12 PM | | GRADDICK WEIR MIRIAN M | Exe V-P, HR | Jan 12 | Sale | 58.00 | 5,000 | 290,000 | 101,484 | Jan 16 05:12 PM | | GLOCER THOMAS H | Director | Nov 08 | Option Exercise | 38.04 | 5,000 | 190,200 | 10,100 | Nov 09 03:52 PM | | GLOCER THOMAS H | Director | Nov 08 | Sale | 56.20 | 5,000 | 280,983 | 5,100 | Nov 09 03:52 PM |
|
|
|
|
|
|
